



Mr. N. Rossignol
European Commission
DG Enterprise & Industry
Unit F2 Pharmaceuticals
45 Avenue d'Auderghem, Office 10/128
1049 Brussels

10 June 2008

**EBE comments on the proposals to amend Annex 1 to Directive 2001/83/EC
as regards Advanced Therapy Medicinal Products**

Dear Mr Rossignol,

I have pleasure in enclosing comments from the European Biopharmaceutical Enterprises (EBE) on the proposals to amend Annex 1 to Directive 2001/83/EC as regards Advanced Therapy Medicinal Products.

I would like to thank you for the opportunity to take part in this consultation exercise and I hope that you will find our comments helpful and constructive.

If you have any questions regarding our comments or you have any further queries, please do not hesitate to contact me.

With kind regards,

Piers Allin
Manager, Regulatory Affairs
European Biopharmaceutical Enterprises